FAQ

MAS063DP

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
012320062017

Related topics

Related topics

5 relations

Narrower (2)

ATOPICLAIRZarzenda

Broader (3)

Dietary FatsGlycyrrhetinic acidPlant Extracts

Related mentions per year

Related mentions per year

1939-2018
19401960198020002020
MAS063DP
Plant Extracts
Dietary Fats
Glycyrrhetinic acid
ATOPICLAIR
Zarzenda

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy of MAS063DP lotion vs 0.02% triamcinolone acetonide lotion in improving post-ablative fractional CO2 laser resurfacing wound healing: a split-face, triple-blinded, randomized, controlled…
Proven as effective acne scar treatment, ablative fractional carbon dioxide (AFCO2 ) laser requires post-laser wound healing care… (More)
Is this relevant?
Review
2017
Review
2017
Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development.
Although some symptoms of dermatologic diseases, such as pruritus and pain, can be subjectively assessed only by patients, the… (More)
Is this relevant?
Review
2009
Review
2009
Atopiclair.
BACKGROUND MAS063DP cream has received marketing authorization in the USA and the EU as a medical device for the relief of… (More)
Is this relevant?
Review
2009
Review
2009
Clinical inquiries. Do nonmedicated topicals relieve childhood eczema?
Emollients are effective first-line treatment to decrease symptoms of eczema and reduce the need to use steroids in children. Tar… (More)
Is this relevant?
2008
2008
MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study.
OBJECTIVE To examine the efficacy and safety of MAS063DP (Atopiclair) cream in the management of mild to moderate atopic… (More)
  • figure 1
Is this relevant?
2008
2008
A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients.
A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted to evaluate the efficacy and safety of… (More)
  • table 1
  • table 2
  • figure 3
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults.
BACKGROUND MAS063DP (Atopiclair) is a topical cream approved for symptomatic relief in the treatment of atopic and contact… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2006
2006
A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults.
BACKGROUND MAS063DP cream has received marketing authorization in the US and the European Union for symptom relief of atopic… (More)
Is this relevant?